Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

187.31 -3.25 (-1.71%)

Streaming Delayed Price Updated: 12:40 PM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

59 60 Next >

$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today ↗

September 04, 2023

Via Benzinga

(BIIB) - Analyzing Biogen's Short Interest ↗

September 01, 2023

Via Benzinga

Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment ↗

August 31, 2023

The company is now focusing on its launch in postpartum depression.

Via Investor's Business Daily

The 7 Most Promising Momentum Stocks to Own Now ↗

August 31, 2023

These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility.

Via InvestorPlace

The 3 Most Promising Pharma Stocks to Own Now ↗

August 30, 2023

A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride.

Via InvestorPlace

Analyst Ratings for Biogen ↗

August 29, 2023

Via Benzinga

Better Buy: Biogen vs. Eli Lilly ↗

August 29, 2023

This battle of biotech giants has a clear winner.

Via The Motley Fool

If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today ↗

August 14, 2023

Via Benzinga

Looking Into Biogen's Recent Short Interest ↗

August 08, 2023

Via Benzinga

Wall Street Thinks This Tiny Biotech Company Could Soar Soon ↗

August 28, 2023

An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle.

Via The Motley Fool

Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock ↗

August 24, 2023

Cassava had $168.4 million of cash at the end of June after losing $28.7 million during the second quarter of 2023. SAVA stock is up 5%

Via InvestorPlace

Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month? ↗

August 24, 2023

The pharmaceutical company's growth prospects have taken a big hit.

Via The Motley Fool

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)

August 17, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Is Sage Therapeutics a Contrarian Buy? ↗

August 08, 2023

A regulatory setback weighed heavily on the drugmaker's shares Monday.

Via The Motley Fool

Biogen Unusual Options Activity For August 02 ↗

August 02, 2023

Via Benzinga

Why Shares of Sage Therapeutics Slumped This Week ↗

August 11, 2023

The company got bad news from the FDA and saw increased losses.

Via The Motley Fool

Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around? ↗

August 10, 2023

The company's rare disease portfolio may soon get an upgrade.

Via The Motley Fool

With an Acquisition on the Way, Is Biogen Stock a Buy? ↗

August 09, 2023

Can the biotech finally get back in the good graces of investors?

Via The Motley Fool

Eli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy? ↗

August 09, 2023

Lilly shares surged 15% in one day to a record high. Here's what you should know.

Via Investor's Business Daily

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: EchoStar Corporation (Nasdaq - SATS), Sovos Brands, Inc. (Nasdaq - SOVO), Reata Pharmaceuticals, Inc. (Nasdaq - RETA), Amedisys, Inc. (Nasdaq – AMED)

August 08, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

August 08, 2023

Piper Sandler raised the price target for Chegg, Inc. (NYSE: CHGG) from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market...

Via Benzinga

What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead ↗

August 07, 2023

The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with postpartum depression (PPD) but issued a Complete Response Letter

Via Benzinga

Dow Rises Over 300 Points To Start The Week ↗

August 07, 2023

The Dow Jones Industrial Average was last seen up 308 points, as the blue-chip index looks to start the week on a high note following its recent losses.

Via Talk Markets

FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says ↗

August 07, 2023

Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.

Via Benzinga

PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories ↗

August 07, 2023

Benzinga

Via Benzinga

August 07, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Why Sage Lost Half Its Value After The FDA Approved Its Depression Drug ↗

August 07, 2023

The company gained approval for the first oral treatment for postpartum depression.

Via Investor's Business Daily

FDA Approves Sage Therapeutics/Biogen's Zuranolone For One Type Of Depression, Rejects For Another ↗

August 07, 2023

The FDA approved Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) Zurzuvae (zuranolone) 50 mg for adults with

Via Benzinga

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

August 04, 2023

From Sage Therapeutics, Inc.

Via Business Wire

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

August 04, 2023

From Biogen Inc.

Via GlobeNewswire

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.